Epicardial Ablation in Brugada Syndrome. An Extension Study of 500 BrS.Patients

Launched by IRCCS POLICLINICO S. DONATO · Apr 4, 2017

Keywords

ClinConnect Summary

This clinical trial is studying a treatment called epicardial ablation for patients with Brugada Syndrome, a condition that can cause abnormal heart rhythms. The trial is an extension of a previous study and aims to see how effective this treatment is in both immediately and over the long term helping to eliminate the heart's abnormal electrical patterns and prevent dangerous heart events like ventricular tachycardia (a fast heart rate) or ventricular fibrillation (a chaotic heart rhythm). The study is currently recruiting participants who are between 18 and 75 years old and have experienced symptoms related to Brugada Syndrome, such as fainting, dizziness, or even cardiac arrest.

To be eligible for this trial, participants must have typical symptoms of Brugada Syndrome or show specific heart patterns on tests. However, those under 18, pregnant women, or individuals with certain other health conditions are not eligible. Participants in this study can expect to receive the epicardial ablation procedure, which involves a small procedure to help correct the heart's electrical patterns. This study represents an important opportunity for those affected by Brugada Syndrome to potentially improve their heart health and reduce the risk of serious heart issues.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Symptomatic BrS patients with typical BrS-related symptoms (cardiac arrest or syncope) or without typical BrS-related symptoms (dizziness, palpitations, presyncope, dyspnea) ICD implantation, spontaneous or ajmaline-induced type 1 Br pattern.
• Exclusion Criteria:
• • Age \< 18 years, prior epicardial ablation, pregnancy, co-morbidities.